HC Wainwright Cuts Earnings Estimates for Heron Therapeutics

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Analysts at HC Wainwright cut their FY2027 earnings per share estimates for Heron Therapeutics in a research note issued on Thursday, April 23rd. HC Wainwright analyst B. Folkes now expects that the biotechnology company will post earnings per share of $0.12 for the year, down from their prior estimate of $0.14. HC Wainwright has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.04) per share. HC Wainwright also issued estimates for Heron Therapeutics’ FY2028 earnings at $0.36 EPS, FY2029 earnings at $0.41 EPS and FY2030 earnings at $0.51 EPS.

A number of other brokerages also recently commented on HRTX. Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Tuesday. Zacks Research upgraded Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, March 27th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $4.50.

Heron Therapeutics Stock Performance

Shares of NASDAQ HRTX opened at $1.19 on Friday. The business’s 50-day moving average price is $0.96 and its two-hundred day moving average price is $1.16. The company has a debt-to-equity ratio of 10.59, a current ratio of 2.48 and a quick ratio of 1.51. Heron Therapeutics has a one year low of $0.74 and a one year high of $2.61. The company has a market capitalization of $224.48 million, a P/E ratio of -9.15 and a beta of 1.42.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Thursday, February 26th. The biotechnology company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. The firm had revenue of $40.59 million during the quarter, compared to analysts’ expectations of $39.53 million.

Institutional Trading of Heron Therapeutics

Large investors have recently made changes to their positions in the stock. B. Riley Wealth Advisors Inc. bought a new stake in shares of Heron Therapeutics during the 2nd quarter worth about $26,000. Advisory Services Network LLC boosted its stake in shares of Heron Therapeutics by 2,383.4% during the 4th quarter. Advisory Services Network LLC now owns 18,874 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 18,114 shares in the last quarter. PKS Advisory Services LLC bought a new stake in shares of Heron Therapeutics during the 3rd quarter worth about $25,000. Russell Investments Group Ltd. bought a new stake in shares of Heron Therapeutics during the 2nd quarter worth about $43,000. Finally, Jones Financial Companies Lllp boosted its stake in shares of Heron Therapeutics by 5,541.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 24,088 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 23,661 shares in the last quarter. Institutional investors own 80.01% of the company’s stock.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.